Market Overview
The Cancer Screening and Precision Oncology Diagnostics Market covers the diagnostic ecosystem used to find cancer earlier, define tumor biology, select targeted treatment, monitor response, and detect recurrence risk. The market includes population screening tests, risk-based screening programs, stool-based and blood-based colorectal cancer screening, mammography, low-dose CT lung screening, cervical HPV testing, prostate cancer testing, comprehensive genomic profiling, companion diagnostics, liquid biopsy, minimal residual disease testing, digital pathology, tumor-informed monitoring, and AI-supported diagnostic interpretation. Therapeutic oncology drugs, radiation treatment, surgery, general imaging not used for oncology diagnosis, and wellness testing without validated oncology relevance are excluded from the scope.Key Report Takeaways
- The Cancer Screening and Precision Oncology Diagnostics Market was valued at USD 51.24 billion in 2025 and is projected to reach USD 116.88 billion by 2032, expanding at a CAGR of 12.5% during 2026 to 2032.
- By product and technology type, cancer screening tests and imaging-based screening led the market with USD 18.90 billion in 2025, representing 36.9% of global revenue.
- Liquid biopsy and MRD testing is the fastest-growing technology segment and is projected to rise from USD 8.62 billion in 2025 to USD 28.40 billion by 2032.
- By cancer type, colorectal cancer remained the largest revenue segment in 2025, while lung cancer is projected to show the fastest growth because of wider low-dose CT screening and broader molecular profiling requirements.
- Hospitals and cancer centers accounted for USD 22.48 billion in 2025, but home-based and decentralized testing channels are gaining the fastest momentum as blood draws, self-sampling, and at-home colorectal screening become more scalable.
- North America generated USD 25.36 billion in 2025 and remained the largest regional market, while Asia-Pacific is the fastest strategic growth region because of rising cancer incidence, expanding screening programs, and rapid adoption of molecular diagnostics.
- The strongest commercial opportunity is shifting from one-time testing to longitudinal oncology decision support, including early detection, therapy selection, recurrence monitoring, and resistance profiling.
The global Cancer Screening and Precision Oncology Diagnostics Market generated USD 51.24 billion in 2025 and is forecast to reach USD 116.88 billion by 2032. This represents a modeled CAGR of 12.5% during 2026 to 2032.Demand is being shaped by the rising global cancer burden, broader screening eligibility, payer interest in earlier detection, increasing use of companion diagnostics with targeted therapy, and the movement from single-marker testing toward broader genomic, multi-omic, and AI-enabled interpretation.
Cancer diagnostics are becoming a strategic infrastructure layer within oncology care. Screening determines whether cancer is detected at a treatable or curable stage. Molecular profiling determines whether a patient is eligible for targeted therapy, immunotherapy, tumor-agnostic treatment, or clinical trial enrollment. Liquid biopsy supports treatment selection when tissue is insufficient and enables repeat testing as tumor biology changes. MRD testing can identify molecular recurrence before radiographic progression. This makes diagnostics central to clinical decisions rather than a supporting laboratory service.
The market is also changing because the historical separation between screening and precision oncology is weakening. Screening was once focused mainly on asymptomatic populations, while precision diagnostics were used mostly in advanced cancer treatment. Blood-based colorectal cancer screening, multi-cancer early detection, ctDNA-based MRD testing, and liquid biopsy-based companion diagnostics are now creating a connected continuum from early detection to treatment monitoring. Companies that can operate across this continuum are expected to capture stronger long-term commercial value than companies focused only on single-use test categories.
Executive Market Snapshot
| Metric | Value |
| Market Size in 2025 | USD 51.24 billion |
| Market Size in 2032 | USD 116.88 billion |
| CAGR 2026 to 2032 | 12.5% |
| Largest Product and Technology Type in 2025 | Cancer Screening Tests and Imaging-Based Screening |
| Fastest-Growing Product and Technology Type | Liquid Biopsy and MRD Testing |
| Largest Cancer Type in 2025 | Colorectal Cancer |
| Fastest-Growing Cancer Type | Lung Cancer |
| Largest End User in 2025 | Hospitals and Cancer Centers |
| Fastest-Growing End User | Home-Based and Decentralized Testing Channels |
| Largest Region in 2025 | North America |
| Fastest Strategic Growth Region | Asia-Pacific |
| Most Important Country Market | USA |
| Strategic Theme | Convergence of early detection, genomic profiling, liquid biopsy, digital pathology, and recurrence monitoring |
Analyst Perspective
The Cancer Screening and Precision Oncology Diagnostics Market should be understood as an oncology decision-enablement market. The commercial value is not limited to the price of a test. The value lies in the clinical action unlocked by the result: whether to screen, biopsy, sequence, select a therapy, change therapy, intensify surveillance, de-escalate treatment, or enroll a patient in a clinical trial. This is why the market becomes more valuable as oncology therapies become more personalized and as health systems push to diagnose cancer earlier.Minimally invasive diagnostics are the most important structural trend. Blood-based colorectal cancer screening, liquid biopsy-based comprehensive genomic profiling, multi-cancer early detection, and tumor-informed MRD testing are changing expectations among physicians, patients, payers, and health systems. Non-invasive and repeatable test formats can increase screening adherence, reduce dependence on limited tissue samples, and support longitudinal monitoring after curative-intent treatment.
The next phase of competition will depend on evidence quality, payer acceptance, and workflow integration. Technical sensitivity and specificity remain important, but they are not enough to win durable adoption. A screening test must show real-world adherence value and acceptable downstream burden. A companion diagnostic must support therapy selection and regulatory requirements. An MRD assay must demonstrate recurrence-risk relevance and clinical decision value. A digital pathology platform must improve speed, consistency, and laboratory workflow without adding interpretation complexity.
Market Dynamics
Market Drivers
Rising Cancer Burden and Earlier Detection Priorities
The strongest market driver is the growing cancer burden and the clinical need to detect tumors before they become advanced or metastatic. Earlier detection can expand treatment options, improve survival for screen-detectable cancers, and reduce the downstream cost intensity of late-stage disease. As cancer incidence rises with aging populations, lifestyle risk factors, and improved diagnostic detection, health systems are placing greater emphasis on colorectal, breast, cervical, lung, prostate, and emerging blood-based screening pathways.Expansion of Biomarker-Directed Oncology Treatment
Precision oncology is expanding because targeted therapies, immunotherapies, antibody-drug conjugates, PARP inhibitors, RET inhibitors, NTRK inhibitors, HER2-directed therapies, EGFR inhibitors, ALK inhibitors, BRAF and MEK combinations, hormone-receptor-directed therapies, and tumor-agnostic drugs frequently depend on molecular or protein-level confirmation. As treatment labels and guidelines become more biomarker-dependent, laboratories and oncology centers are adopting broader genomic panels, immunohistochemistry, fluorescence in situ hybridization, PCR assays, and liquid biopsy platforms.Liquid Biopsy Is Expanding Across Screening, Profiling, and MRD
Liquid biopsy is moving beyond advanced cancer profiling into multiple points of the oncology pathway. In advanced disease, it supports therapy selection when tissue is limited and helps detect emerging resistance. In early-stage cancer, ctDNA-based MRD testing can identify patients at higher recurrence risk after surgery or systemic treatment. In population screening, blood-based tests are creating a more patient-friendly route for colorectal cancer screening and are shaping the long-term commercial debate around multi-cancer early detection.Digital Pathology and AI Are Improving Diagnostic Throughput
Pathology workloads, biomarker complexity, and demand for faster turnaround times are increasing the importance of digital pathology and AI-supported interpretation. Whole-slide imaging, computational pathology, image-based biomarker analysis, and AI triage can improve standardization and help laboratories manage higher testing volumes. These platforms are especially relevant in precision oncology because small interpretation differences can influence eligibility for high-value therapies.Market Restraints
Evidence Thresholds Remain High for Screening Tests
The largest restraint is the high evidence standard required for tests used in asymptomatic populations. Screening programs must balance cancer detection with false positives, false negatives, overdiagnosis, patient anxiety, procedure capacity, cost effectiveness, and clinical utility. Multi-cancer early detection tests may create significant long-term opportunity, but broad adoption will require prospective evidence showing stage shift, acceptable cancer signal localization, manageable false-positive rates, and payer confidence.Reimbursement and Access Remain Uneven Across Test Categories
Established screening categories such as mammography and colorectal screening benefit from guideline support and established payer routes. Newer liquid biopsy, MRD, and MCED tests face more variable reimbursement, especially when testing is repeated, used outside a therapy label, or applied to broader populations. This creates a gap between technical capability and commercial adoption. Companies with clinical utility evidence, FDA-reviewed claims, and clear economic value will be better positioned than companies relying only on analytical performance.Operational Complexity Limits Full-Scale Precision Oncology Adoption
Precision oncology diagnostics require reliable tissue handling, adequate samples, fast turnaround, variant interpretation, bioinformatics, tumor board review, reporting integration, reimbursement operations, data privacy controls, and sometimes genetic counseling. In lower-resource markets, shortages of trained pathologists, limited molecular laboratory infrastructure, and uneven access to targeted therapies can slow adoption even when diagnostic technology is available.Market Opportunities
The strongest opportunities sit at the intersection of convenience, clinical utility, and longitudinal care. Blood-based screening can improve participation among individuals who avoid colonoscopy or stool collection. MRD testing can help identify recurrence risk earlier than conventional imaging in selected cancers. Comprehensive genomic profiling can match patients with targeted therapies or trials. Digital pathology can improve biomarker interpretation and laboratory productivity. The most defensible businesses will combine regulatory credibility, payer evidence, physician trust, and sample collection reach.Market Segmentation Analysis
By Product and Technology Type
| Segment | 2025 | 2025 Share | 2032 | Strategic Interpretation |
| Cancer Screening Tests and Imaging-Based Screening | USD 18.90 billion | 36.9% | USD 38.50 billion | Largest segment because breast, colorectal, cervical, lung, and prostate screening represent recurring population-level testing pools. |
| Molecular and Companion Diagnostics | USD 13.75 billion | 26.8% | USD 32.90 billion | Growth is linked to targeted therapies, immunotherapy biomarkers, tumor-agnostic indications, and broader genomic profiling. |
| Liquid Biopsy and MRD Testing | USD 8.62 billion | 16.8% | USD 28.40 billion | Fastest-growing segment because blood-based profiling, recurrence monitoring, and early detection enable repeatable testing across the cancer journey. |
| Digital Pathology and AI-Enabled Diagnostic Platforms | USD 9.97 billion | 19.5% | USD 17.08 billion | Expands through whole-slide imaging, computational pathology, biomarker quantification, and remote expert review. |
Molecular and Companion Diagnostics generated USD 13.75 billion in 2025 and are projected to reach USD 32.90 billion by 2032. The segment includes comprehensive genomic profiling, PCR-based mutation testing, immunohistochemistry, fluorescence in situ hybridization, tumor mutational burden, microsatellite instability, homologous recombination deficiency testing, and approved companion diagnostic assays. Growth is being driven by the expanding number of therapies that require biomarker-defined patient selection.
Liquid Biopsy and MRD Testing generated USD 8.62 billion in 2025 and are projected to reach USD 28.40 billion by 2032, making it the fastest-growing product and technology category. This segment benefits from repeatability, tissue-sparing utility, convenience, and the ability to capture evolving tumor biology. It includes blood-based tumor profiling, therapy-selection liquid biopsy, recurrence monitoring, tumor-informed MRD, tumor-agnostic MRD approaches, and multi-cancer early detection programs.
Digital Pathology and AI-Enabled Diagnostic Platforms generated USD 9.97 billion in 2025 and are projected to reach USD 17.08 billion by 2032. The segment includes whole-slide imaging, AI-assisted interpretation, image-based biomarker analysis, digital workflow systems, and computational pathology companion diagnostic tools. Growth is supported by pathologist workload pressure, remote review needs, standardization demand, and increasing biomarker complexity.
By Cancer Type
| Cancer Type | 2025 | CAGR | 2032 | Market Position |
| Colorectal Cancer | USD 12.46 billion | 24.3% | USD 25.90 billion | Largest indication because screening is supported by stool testing, colonoscopy pathways, and blood-based screening innovation. |
| Breast Cancer | USD 10.38 billion | 20.3% | USD 22.20 billion | Large screening base and expanding biomarker testing in advanced and early-stage disease. |
| Lung Cancer | USD 9.62 billion | 18.8% | USD 24.60 billion | Fastest-growing major indication because of low-dose CT eligibility and broad molecular profiling in NSCLC. |
| Prostate Cancer | USD 7.45 billion | 14.5% | USD 15.50 billion | Supported by PSA pathways, MRI-linked diagnosis, hereditary risk testing, and HRR testing. |
| Other Solid Tumors | USD 11.33 billion | 22.1% | USD 28.68 billion | Includes ovarian, pancreatic, gastric, liver, bladder, kidney, melanoma, endometrial, head and neck, and tumor-agnostic testing. |
Breast Cancer generated USD 10.38 billion in 2025 and is projected to reach USD 22.20 billion by 2032. The segment remains large because breast cancer combines high screening intensity with expanding molecular requirements. Mammography, digital breast tomosynthesis, ultrasound and MRI in selected patients, HER2 testing, hormone receptor testing, ESR1 testing, PIK3CA testing, HRD testing, PD-L1 testing where relevant, and liquid biopsy in advanced disease all support demand.
Lung Cancer generated USD 9.62 billion in 2025 and is projected to reach USD 24.60 billion by 2032, making it the fastest-growing major cancer type. Low-dose CT screening supports early detection in high-risk populations, while advanced non-small cell lung cancer increasingly requires broad molecular profiling for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, HER2, PD-L1, and emerging biomarkers. Liquid biopsy is particularly relevant because tissue samples are often limited and repeat biopsies may be difficult.
Prostate Cancer generated USD 7.45 billion in 2025 and is projected to reach USD 15.50 billion by 2032. The segment includes PSA testing, reflex biomarkers, MRI-linked diagnostic workflows, hereditary risk assessment, genomic risk stratification, BRCA testing, homologous recombination repair testing, and companion diagnostics in advanced disease. Growth is being shaped by better risk stratification and the broader use of molecular testing in metastatic and castration-resistant disease.
Other Solid Tumors generated USD 11.33 billion in 2025 and are projected to reach USD 28.68 billion by 2032. This group includes ovarian, pancreatic, gastric, esophageal, melanoma, liver, bladder, kidney, thyroid, endometrial, head and neck, and tumor-agnostic applications. Growth is supported by comprehensive genomic profiling, immunotherapy biomarkers, tumor-agnostic approvals, MRD studies, and early detection demand in cancers without established screening programs.
By End User
| End User | 2025 | Share | 2032 | Growth Logic |
| Hospitals and Cancer Centers | USD 22.48 billion | 43.9% | USD 48.70 billion | Largest end-user group because oncology diagnosis, biopsy, pathology, molecular tumor boards, and treatment selection are concentrated in specialist centers. |
| Diagnostic Laboratories | USD 15.95 billion | 31.1% | USD 39.90 billion | High-throughput workflows, reference testing, bioinformatics, liquid biopsy, and at-home sample logistics support growth. |
| Academic and Research Institutions | USD 6.43 billion | 12.5% | USD 12.88 billion | Important for biomarker discovery, translational oncology, screening studies, MRD validation, and AI pathology research. |
| Home-Based and Decentralized Testing Channels | USD 6.38 billion | 12.5% | USD 15.40 billion | Fastest-growing channel due to self-sampling, mobile phlebotomy, decentralized blood collection, and screening adherence programs. |
Diagnostic Laboratories generated USD 15.95 billion in 2025 and are projected to reach USD 39.90 billion by 2032. Independent molecular laboratories, reference laboratories, pathology labs, genomic testing companies, and centralized screening laboratories are scaling through high-throughput testing, at-home sample logistics, companion diagnostic panels, MRD testing, and strong reimbursement operations.
Academic and Research Institutions generated USD 6.43 billion in 2025 and are projected to reach USD 12.88 billion by 2032. These organizations are important because many screening protocols, biomarkers, MRD assays, AI pathology tools, and genomic interpretation frameworks are validated in research settings before broader clinical commercialization.
Home-Based and Decentralized Testing Channels generated USD 6.38 billion in 2025 and are projected to reach USD 15.40 billion by 2032, making this the fastest-growing channel. At-home colorectal screening, self-sampling programs, mobile phlebotomy, decentralized blood collection, senior-living screening access, and direct-to-provider ordering networks can improve participation and extend access beyond hospital settings.
Regional Analysis
| Region or Country | 2025 | 2032 | Strategic Role |
| North America | USD 25.36 billion | USD 54.20 billion | Largest regional market with high oncology spending, strong screening guidelines, advanced cancer centers, and early liquid biopsy adoption. |
| USA | USD 22.70 billion | USD 48.60 billion | Most important country market because of large eligible screening populations and strong precision oncology commercialization. |
| Europe | USD 13.45 billion | USD 30.60 billion | Major market supported by organized screening programs, public health policy, and growing precision oncology adoption. |
| Germany | USD 3.76 billion | USD 8.46 billion | Largest European opportunity with advanced hospital infrastructure and strong pathology networks. |
| France | USD 2.62 billion | USD 5.92 billion | Important market with organized screening, national cancer planning, and centralized reimbursement evaluation. |
| Asia-Pacific | USD 12.43 billion | USD 32.08 billion | Fastest strategic growth region because of rising cancer incidence, expanding healthcare access, and rapid molecular diagnostics adoption. |
| Japan | USD 3.21 billion | USD 7.76 billion | Advanced market supported by aging demographics, high cancer burden, and selected adoption of precision oncology. |
| China | USD 5.24 billion | USD 14.85 billion | Largest Asia-Pacific opportunity with population scale, hospital modernization, and strong domestic diagnostics competition. |
| South Korea | USD 1.06 billion | USD 2.72 billion | Strategically attractive market with national screening programs, digital health capability, and high specialist access. |
North America Cancer Screening and Precision Oncology Diagnostics Market
North America generated USD 25.36 billion in 2025, representing 49.5% of global revenue, and is projected to reach USD 54.20 billion by 2032. The region leads because of high oncology spending, broad screening recommendations, advanced cancer centers, strong molecular laboratory infrastructure, established payer pathways for selected diagnostics, and rapid commercialization of liquid biopsy and MRD testing. The United States accounts for most regional revenue and remains the primary launch market for high-value oncology diagnostics.USA Cancer Screening and Precision Oncology Diagnostics Market
The USA generated USD 22.70 billion in 2025 and is projected to reach USD 48.60 billion by 2032. The country combines large eligible screening populations, early access to innovative diagnostics, broad biomarker requirements in oncology drugs, and a mature private and public payer infrastructure. Companies with FDA-approved tests, guideline support, payer evidence, and broad sample collection networks are expected to hold stronger competitive positions than companies with only technical differentiation.Europe Cancer Screening and Precision Oncology Diagnostics Market
Europe generated USD 13.45 billion in 2025 and is projected to reach USD 30.60 billion by 2032. The region benefits from organized screening programs, public health initiatives, strong pathology networks, and growing use of precision oncology diagnostics. Adoption is shaped by health technology assessment, national reimbursement processes, public procurement, and evidence standards. Europe will favor tests that improve outcomes, reduce unnecessary procedures, and demonstrate cost-effective integration into care pathways.Germany Cancer Screening and Precision Oncology Diagnostics Market
Germany generated USD 3.76 billion in 2025 and is projected to reach USD 8.46 billion by 2032. Germany is the largest European country opportunity because of its advanced hospital infrastructure, specialist oncology networks, established pathology base, and ability to adopt molecular testing when clinical value is clear. The market is attractive for comprehensive genomic profiling, colorectal and breast screening, lung cancer diagnostics, and digital pathology.France Cancer Screening and Precision Oncology Diagnostics Market
France generated USD 2.62 billion in 2025 and is projected to reach USD 5.92 billion by 2032. The country is important because of national cancer planning, organized screening programs, hospital-based oncology infrastructure, and centralized reimbursement evaluation. The best commercial opportunities will be diagnostics that improve pathway efficiency, support targeted therapy access, or reduce unnecessary invasive procedures.Asia-Pacific Cancer Screening and Precision Oncology Diagnostics Market
Asia-Pacific generated USD 12.43 billion in 2025 and is projected to reach USD 32.08 billion by 2032, making it the fastest strategic growth region. Growth is driven by rising cancer incidence, expanding private healthcare, government screening programs, increasing use of targeted oncology therapies, and broader molecular diagnostics infrastructure in Japan, China, South Korea, Australia, Singapore, and India. The region will reward companies that can combine high-quality testing with cost-sensitive access models.Japan Cancer Screening and Precision Oncology Diagnostics Market
Japan generated USD 3.21 billion in 2025 and is projected to reach USD 7.76 billion by 2032. The country is a major diagnostics market because of its aging population, high cancer burden, advanced hospital system, and selected adoption of precision oncology. Genomic profiling, lung cancer testing, gastric cancer diagnostics, colorectal screening, and companion diagnostics are expected to remain key growth areas.China Cancer Screening and Precision Oncology Diagnostics Market
China generated USD 5.24 billion in 2025 and is projected to reach USD 14.85 billion by 2032. China is the largest Asia-Pacific opportunity because of population scale, high cancer burden, rapid hospital modernization, increasing use of targeted therapies, and a strong domestic diagnostics industry. Demand is strongest in lung, colorectal, gastric, liver, breast, and cervical cancer, with molecular testing expanding fastest in tertiary hospitals.South Korea Cancer Screening and Precision Oncology Diagnostics Market
South Korea generated USD 1.06 billion in 2025 and is projected to reach USD 2.72 billion by 2032. The country is smaller than China or Japan but strategically attractive because of strong national screening programs, advanced hospital infrastructure, digital health capability, and rapid precision oncology adoption when reimbursement is available. The market is well suited for genomic profiling, AI-supported pathology, lung cancer diagnostics, breast cancer testing, and gastrointestinal cancer screening.Competitive Landscape
The Cancer Screening and Precision Oncology Diagnostics Market is semi-consolidated at the platform level but fragmented across individual use cases. Large diagnostics companies, genomic testing firms, liquid biopsy specialists, imaging technology providers, pathology platforms, and laboratory networks all compete across different stages of the oncology pathway. No single company controls the full market because screening, molecular profiling, pathology, imaging, MRD, and MCED require different regulatory, clinical, operational, and commercial capabilities. Competition is increasingly defined by clinical utility, payer coverage, regulatory status, and workflow integration. Technical performance is essential, but it is not sufficient. Screening products must demonstrate sensitivity, specificity, adherence benefit, and acceptable downstream burden. Companion diagnostics must be linked to treatment selection and regulatory pathways. MRD assays must show recurrence-risk relevance and clinical decision value. Digital pathology solutions must fit laboratory workflows and produce reliable, reproducible outputs. The market is moving toward longitudinal care models. Companies are expanding from single tests into platforms that support screening, diagnosis, treatment selection, recurrence monitoring, and therapy resistance assessment. This favors companies with broad test menus, high-quality data assets, payer relationships, regulatory execution, health-system partnerships, physician engagement, and reliable sample collection infrastructure.Key Company Profiles
Guardant Health
Guardant Health is one of the most strategically important companies in the market because it operates across precision oncology liquid biopsy, colorectal cancer screening, and recurrence monitoring. Guardant360 CDx supports comprehensive genomic profiling and companion diagnostic applications across solid tumors, while Shield is positioned as a blood-based colorectal cancer screening test. The company’s strategy is centered on moving liquid biopsy across the cancer care continuum from early detection to therapy selection and monitoring.The company’s collaboration with Quest Diagnostics to broaden Shield ordering and blood collection access is commercially meaningful because blood-based screening requires more than regulatory approval. It also requires convenient physician ordering, broad collection infrastructure, payer confidence, and patient adherence.
Exact Sciences
Exact Sciences is a leading cancer screening and molecular diagnostics company with a strong position in colorectal cancer screening through Cologuard and Cologuard Plus. The company benefits from brand recognition, at-home sample collection infrastructure, physician familiarity, and large-scale laboratory operations. Cologuard Plus strengthens its position in average-risk adults aged 45 and older and demonstrates how established screening companies are improving test performance while preserving patient convenience.Exact Sciences is also expanding beyond stool-based colorectal screening into MRD and multi-cancer early detection research. This strategy is important because the long-term oncology diagnostics opportunity is shifting from isolated screening tests to multi-stage platforms that can support early detection, recurrence monitoring, and disease management.
GRAIL
GRAIL is a central company in multi-cancer early detection through the Galleri test. The company’s FDA PMA submission for Galleri is a major milestone because regulatory authorization could materially influence payer and health-system confidence in MCED testing. Galleri’s commercial potential depends on prospective population-scale evidence, stage-shift data, acceptable false-positive burden, and health-system readiness to manage cancer signal localization and follow-up.The NHS-Galleri trial is strategically important because it evaluates annual multi-cancer screening at population scale. MCED adoption will depend not only on cancer detection rates but also on whether testing can shift diagnosis toward earlier stages, reduce late-stage burden, and fit into real-world clinical pathways without overloading diagnostic capacity.
Roche and Foundation Medicine
Roche and Foundation Medicine represent one of the strongest precision oncology diagnostic platforms. FoundationOne CDx is a tissue-based comprehensive genomic profiling test used to provide clinically actionable information across solid tumors, while FoundationOne Liquid CDx supports blood-based genomic profiling. The platform has strategic value because it links diagnostics with therapy selection, companion diagnostic indications, clinical trial matching, and broader oncology decision support.Roche is also investing in digital pathology and computational companion diagnostics. This positions the company to participate not only in molecular testing but also in image-based biomarker interpretation, pathology workflow modernization, and AI-supported diagnostic decision-making.
Natera
Natera is a major player in molecular residual disease testing through Signatera. The company positions Signatera as a tumor-informed MRD assay across multiple tumor types and focuses on recurrence-stage precision oncology, where ctDNA detection can help identify patients at higher risk after curative-intent therapy.Natera’s strategic opportunity is tied to evidence generation, guideline inclusion, payer coverage, and integration into treatment decision pathways. If MRD testing demonstrates consistent clinical utility across major solid tumors, it could become a recurring diagnostic category with strong commercial durability.
Recent Developments
- In March 2026, Guardant Health announced that Shield became accessible through Quest Diagnostics’ national test ordering and collection network. This expands physician ordering and blood collection access for colorectal cancer screening.
- In March 2026, Exact Sciences announced AACR presentations covering molecular residual disease testing and multi-cancer early detection data. This reflects the company’s continued movement beyond colorectal screening into broader oncology diagnostics.
- In February 2026, GRAIL announced topline findings from the NHS-Galleri trial, a randomized controlled evaluation of annual multi-cancer screening with Galleri in England’s National Health Service. The results are important for the future evidence debate around MCED testing.
- In January 2026, GRAIL submitted the final module of its FDA PMA application for the Galleri multi-cancer early detection test. FDA authorization could materially influence the commercial pathway for MCED adoption.
- In 2024 and 2025, FDA approvals for Shield and Cologuard Plus strengthened the regulated commercial category for non-invasive colorectal cancer screening in average-risk adults aged 45 and older.
Strategic Outlook
The Cancer Screening and Precision Oncology Diagnostics Market is positioned for sustained expansion through 2032 as oncology care becomes more prevention-oriented, biomarker-driven, and longitudinal. Screening will remain the largest revenue foundation because of recurring volumes in colorectal, breast, cervical, lung, and prostate cancer. However, the strongest growth will come from liquid biopsy, MRD, comprehensive genomic profiling, and multi-cancer early detection because these categories connect directly to treatment selection, recurrence monitoring, and earlier diagnosis.The next phase of the market will be defined by evidence and access. Technologies with strong analytical performance but weak clinical utility evidence will struggle to achieve broad adoption. Tests that show improved adherence, earlier diagnosis, lower invasive procedure burden, therapy-selection value, recurrence-risk stratification, or workflow efficiency will gain stronger payer and physician support. Regulatory approval or clearance will become increasingly important in high-impact categories such as MCED, companion diagnostics, and MRD-based treatment decision support.
By 2032, the market is expected to be more integrated, data-rich, and platform-driven. North America should remain the largest monetization base because of high oncology spending, innovative diagnostics adoption, and strong liquid biopsy commercialization. Asia-Pacific should grow fastest because of rising cancer incidence, expanding screening programs, and rapid molecular diagnostics adoption in China, Japan, and South Korea. Companies best positioned to win will combine validated test performance, regulatory credibility, payer evidence, broad sample collection access, high-quality reporting, and the ability to support oncology decisions from early detection through treatment monitoring.